ATR inhibitor camonsertib (RP-3500) suppresses early-stage erythroblasts by mediating ferroptosis

M. Levy; G. B. Ferraro; M. Planoutene; L. Li; Y. Han; L. Varicchio; S. Fournier; X. An; S. J. Morris; M. Koehler; R. Hoffman; A. J. Fretland; A. Roulston; Y. Z. Ginzburg

doi:10.1016/S0959-8049(22)01064-4

ATR inhibitor camonsertib (RP-3500) suppresses early-stage erythroblasts by mediating ferroptosis

M. Levy, G. B. Ferraro, M. Planoutene, L. Li, Y. Han, L. Varicchio, S. Fournier, X. An, S. J. Morris, M. Koehler, R. Hoffman, A. J. Fretland, A. Roulston, Y. Z. Ginzburg

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	S100
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)01064-4
State	Published - Oct 2022

Access to Document

10.1016/S0959-8049(22)01064-4

Cite this

Levy, M., Ferraro, G. B., Planoutene, M., Li, L., Han, Y., Varicchio, L., Fournier, S., An, X., Morris, S. J., Koehler, M., Hoffman, R., Fretland, A. J., Roulston, A., & Ginzburg, Y. Z. (2022). ATR inhibitor camonsertib (RP-3500) suppresses early-stage erythroblasts by mediating ferroptosis. European Journal of Cancer, 174, S100. https://doi.org/10.1016/S0959-8049(22)01064-4

@article{62506ac01163429ea985a8dea3ba6b60,

title = "ATR inhibitor camonsertib (RP-3500) suppresses early-stage erythroblasts by mediating ferroptosis",

author = "M. Levy and Ferraro, {G. B.} and M. Planoutene and L. Li and Y. Han and L. Varicchio and S. Fournier and X. An and Morris, {S. J.} and M. Koehler and R. Hoffman and Fretland, {A. J.} and A. Roulston and Ginzburg, {Y. Z.}",

note = "Funding Information: Corporate-sponsored Research: RH and YZG receive sponsored research funding from Repare Therapeutics.",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)01064-4",

language = "English",

volume = "174",

pages = "S100",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - ATR inhibitor camonsertib (RP-3500) suppresses early-stage erythroblasts by mediating ferroptosis

AU - Levy, M.

AU - Ferraro, G. B.

AU - Planoutene, M.

AU - Li, L.

AU - Han, Y.

AU - Varicchio, L.

AU - Fournier, S.

AU - An, X.

AU - Morris, S. J.

AU - Koehler, M.

AU - Hoffman, R.

AU - Fretland, A. J.

AU - Roulston, A.

AU - Ginzburg, Y. Z.

N1 - Funding Information: Corporate-sponsored Research: RH and YZG receive sponsored research funding from Repare Therapeutics.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140471706&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)01064-4

DO - 10.1016/S0959-8049(22)01064-4

M3 - Article

AN - SCOPUS:85140471706

SN - 0959-8049

VL - 174

SP - S100

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -